Laster Wr
Impact in
- Oncology top 5%
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Drug Transport and Resistance Mechanisms
- Hematology top 10%
Papers in
-
- Cancer therapeutics and mechanisms 8
- Retinoids in leukemia and cellular processes 2
- Oncology 10
- Cancer Treatment and Pharmacology 5
- Co-authors
- Schabel Fm (24 shared papers)Trader Mw (14 shared papers)Griswold Dp (9 shared papers)Corbett Th (4 shared papers)Skipper He (13 shared papers)Montgomery Ja (3 shared papers)Linda Simpson‐Herren (3 shared papers)Wilcox Ws (3 shared papers)
- Journals
- Cancer Research (1 paper)PubMed (27 papers)
- Partner nations
- United States
In The Last Decade
Laster Wr
28 papers receiving 996 citations
Laster Wr's Hit Papers
Peers
Comparison fields: 5 of 90
- Oncology 542
- Hematology 114
- Genetics 86
- Cancer Research 118
- Pulmonary and Respiratory Medicine 218
Countries citing papers authored by Laster Wr
This map shows the geographic impact of Laster Wr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laster Wr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laster Wr more than expected).
Fields of papers citing papers by Laster Wr
This network shows the impact of papers produced by Laster Wr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laster Wr. The network helps show where Laster Wr may publish in the future.
Co-authors
The 13 scholars most cited alongside Laster Wr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Hit paper breakdown → | 1980 | 357 |
| 2 | Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. | 1963 | 256 |
| 3 | Establishment of cross-resistance profiles for new agents. | 1983 | 92 |
| 4 | Concepts for controlling drug-resistant tumor cells. | 1980 | 43 |
| 5 | Success and failure in the treatment of solid tumors. II. Kinetic parameters and "cell cure" of moderately advanced carcinoma 755. | 1969 | 41 |
| 6 | Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite. | 1973 | 37 |
| 7 | Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. | 1982 | 37 |
| 8 | Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors. | 1965 | 35 |
| 9 | Toxicity studies in mice treated with 1-beta-D-arabinofuranosylcytosine (ara-C). | 1969 | 31 |
| 10 | Spontaneous AK leukemia (lymphoma) as a model system. | 1969 | 26 |
| 11 | Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. | 1987 | 25 |
| 12 | Response to therapy of spontaneous, first passage, and long passage lines of AK leukemia. | 1969 | 24 |
| 13 | Basic and therapeutic trial results obtained in the spontaneous AK leukemia (lymphoma) model-end of 1971. | 1972 | 23 |
| 14 | Experimental evaluation of potential anticancer agents. I. Quantitative therapeutic evaluation of certain purine analogs. | 1961 | 23 |
| 15 | Success and failure in the treatment of solid tumors. 3. "Cure" of metastatic Lewis lung carcinoma with methyl-CCNU (NSC-95442) and surgery-chemotherapy. | 1972 | 23 |
| 16 | Evaluation of whole-body hyperthermia as an adjunct to chemotherapy in murine tumors. | 1979 | 23 |
| 17 | Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. | 1990 | 20 |
| 18 | Experimental evaluation of potential anticancer agents. 28. Effects of therapy on viability and rate of proliferation of leukemic cells in various anatomic sites. | 1965 | 17 |
| 19 | Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056). | 1976 | 15 |
| 20 | Experimental evaluation of potential anticancer agents. XX. Development of immunity to leukemia L1210 in BDF mice and effects of therapy. | 1966 | 11 |
About Laster Wr
Laster Wr is a scholar working on Molecular Biology, Oncology, Public Health, Environmental and Occupational Health, Organic Chemistry and Radiology, Nuclear Medicine and Imaging, having authored 28 papers that have together received 1.2k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (8 papers), Cancer therapeutics and mechanisms (8 papers), Cancer Treatment and Pharmacology (5 papers), Chronic Myeloid Leukemia Treatments (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Click Chemistry and Applications (2 papers), Retinoids in leukemia and cellular processes (2 papers) and HIV/AIDS drug development and treatment (2 papers). The work is most often cited by research in Oncology (542 citations), Hematology (114 citations), Genetics (86 citations), Cancer Research (118 citations) and Pulmonary and Respiratory Medicine (218 citations). Laster Wr has collaborated with scholars based in United States. Frequent co-authors include Schabel Fm, Trader Mw, Griswold Dp, Corbett Th, Skipper He, Montgomery Ja, Linda Simpson‐Herren, Wilcox Ws, Thomson and Emil Frei. Their work appears in journals such as Cancer Research and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.